Related Experiment Video
Updated: Feb 13, 2026

Perspectives on Neuroscience
Published on: July 31, 2007
Anti-Angiogenics: Current Situation and Future Perspectives
Abstract:
Angiogenesis, the process leading to the formation of new blood vessels, is one of the hallmarks of cancer. Extensive studies established that i) vascular endothelial growth factor (VEGF) is a key driver of sprouting angiogenesis, ii) VEGF is overexpressed in most solid cancers, and iii) inhibition of VEGF can suppress tumor growth in animal models. This has led to the development of pharmacological agents for anti-angiogenesis to disrupt the vascular supply and starve the tumor of nutrients and oxygen, primarily through the blockade of VEGF/VEGF receptor signaling. This effort has resulted in 11 anti-VEGF drugs approved for certain advanced cancers, either alone or in combination with chemotherapy and other targeted therapies. However, inhibition of VEGF signaling is not effective in all cancers, and anti-angiogenics have often only limited impact on overall survival of cancer patients. This review focuses on the current status of FDA-approved anti-angiogenic antibodies and tyrosine kinase inhibitors and summarizes the progress and future directions of VEGF-targeted therapy.
Insights
Anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) are approved for cancers. However, their effectiveness varies, prompting a review of current VEGF-targeted drugs and future directions.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth.
- Vascular Endothelial Growth Factor (VEGF) drives angiogenesis and is overexpressed in many cancers.
- VEGF signaling blockade is a strategy for anti-angiogenic cancer therapy.
Purpose of the Study:
- To review FDA-approved anti-angiogenic antibodies and tyrosine kinase inhibitors targeting VEGF.
- To summarize the progress and future directions of VEGF-targeted cancer therapy.
Main Methods:
- Review of current literature on VEGF-targeted therapies.
- Analysis of FDA-approved anti-angiogenic drugs (antibodies and tyrosine kinase inhibitors).
Main Results:
- 11 anti-VEGF drugs are approved for advanced cancers, used alone or with other treatments.
- VEGF inhibition shows variable efficacy across different cancer types.
- Anti-angiogenic therapies often have limited impact on overall patient survival.
Conclusions:
- VEGF-targeted therapies represent a significant advancement in cancer treatment.
- Further research is needed to overcome resistance and improve outcomes with anti-angiogenic drugs.
- Future directions include optimizing combination therapies and exploring novel therapeutic strategies.
More Related Videos
Related Concept Videos
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Social Cognitive Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Electrical Current

